SAN DIEGO, March 4, 2026 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the “Class Period”), have until Monday, April 6,…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
